SedlyarovaNadia IlluminaUnited States

This symposium addresses the critical shift toward multi-resolution, multi-modal approaches that enable the precise deconstruction of the tumor ecosystem to achieve a system-level understanding of cancer progression. The session will begin with an overview of emerging innovations expanding the resolution and scope of cancer research, followed by expert‑led research demonstrating the utility of spatial transcriptomics for tumor microenvironment analysis and high‑plex functional proteomics for uncovering protein‑level drivers of cancer biology. Building on these applications and using Illumina Connected Multiomics (ICM) as a framework, an R&D‑led technical deep dive will examine analytical considerations for single‑omic and integrated multiomic analysis across single‑cell, spatial, transcriptomic, proteomic, genomic, and epigenomic data. Through practical examples, this session will demonstrate how AI guided workflows, structured data exploration, and intuitive visualisation make advanced multiomic analysis accessible, enabling researchers to confidently apply multiomic approaches in their own studies. Join us to explore how these multidimensional results, powered by high‑fidelity sequencing and accessible data analytics are providing the clarity needed to decipher the functional drivers of cancer and advance the next wave of precision oncology.

FFPE is the most abundant clinical sample type used in cancer research. However, extracting high-quality genomic, transcriptomic, and proteomic data from FFPE remains a major challenge. This symposium explores robust and reliable sample preparation workflows that transform FFPE from a difficult specimen into a powerful resource for multi-Omics analysis. Experts will highlight AFA enabled workflows that maximize analyte recovery, preserve molecular integrity, and deliver confident results for DNA, RNA, and proteins. Discover how integrated, automation ready workflows can provide deeper insights from FFPE, thereby accelerating biomarker discovery, translational research, and precision oncology.